All In Biotech

Drug Trial Radar · NCT07120503

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 in Adult Participants With Moderate or Severe Asthma

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jul 24, 2025

Primary completion

Oct 1, 2028

Study completion Nov 23, 2028

Sponsor

Lead sponsor
Windward BioIndustry
Sponsor type
Industry
First posted
Aug 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global Phase 2 study divided in two parts. Part A is a double-blind, randomized dose-range finding study in adults with moderate to severe asthma to confirm the dosing regimen of WIN378 that can be tested in future pivotal trials for efficacy and safety. Part B is a pivotal double-blind, randomized study to demonstrate the efficacy and safety of WIN378 in adults with severe uncontrolled asthma. Two dose levels of WIN378 will be tested against placebo to evaluate AAER, lung function, asthma control, asthma-related quality of life and other important efficacy endpoints.

Conditions

  • Asthma

Interventions

  • WIN378Drug

    WIN378 is a fully human, ultra-long-acting monoclonal antibody given twice-yearly that binds to thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving asthma control over the extended dosing interval.

  • PlaceboDrug

    A sham injection consisting of placebo to mask WIN378.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PART A: Number of participants with treatment-emergent adverse events (TEAEs) during the studyTime frame: Week 0 - Week 60
  2. PART A: Number of participants with treatment-emergent serious adverse events (TESAEs) during the studyTime frame: Week 0 - Week 60
  3. PART A: Number of participants with abnormal vital signs during the studyTime frame: Week 0 - Week 60
  4. PART A: Number of participants with abnormal laboratory assessments during the studyTime frame: Week 0 - Week 60
  5. PART A: Number of participants with Clinically significant abnormal ECG results during the studyTime frame: Week 0 - Week 60
  6. PART A: WIN 378 Pharmacokinetics: concentration at trough [Ctrough]Time frame: Week 0 - Week 60
  7. PART A: WIN 378 Pharmacokinetics: area under the concentration time curve [AUC]Time frame: Week 0 - Week 60
  8. PART A: WIN 378 Pharmacokinetics: maximum observed concentration [Cmax])Time frame: Week 0 - Week 60
  9. PART A: Number of participants with positive anti-drug antibodies (ADA) during the studyTime frame: Week 0 - Week 60
  10. PART B: Annualized Asthma Exacerbation Rate (AAER)Time frame: 24 Weeks after last dose

Locations

73 sites in 8 countries. Site status is shown where the registry gives one.

  • WB Contracted Clinical Research Site

    Los Angeles, California · Active not recruiting

  • WB Contracted Clinical Research Site

    San Jose, California · Active not recruiting

  • WB Contracted Clinical Research Site

    Melbourne, Florida · Recruiting

  • WB Contracted Clinical Research Site

    Miami, Florida · Active not recruiting

  • WB Contracted Clinical Research Site

    White Marsh, Maryland · Active not recruiting

  • WB Contracted Clinical Research Site

    Stow, Massachusetts · Active not recruiting

  • WB Contracted Clinical Research Site

    Detroit, Michigan · Active not recruiting

  • WB Contracted Clinical Research Site

    Richfield, Minnesota · Active not recruiting

  • WB Contracted Clinical Research Site

    St Louis, Missouri · Active not recruiting

  • WB Contracted Clinical Research Site

    Bellevue, Nebraska · Active not recruiting

  • WB Contracted Clinical Research Site

    Toledo, Ohio · Recruiting

  • WB Contracted Clinical Research Site

    Edmond, Oklahoma · Active not recruiting

  • WB Contracted Clinical Research Site

    Pittsburgh, Pennsylvania · Active not recruiting

  • WB Contracted Clinical Research Site

    Charleston, South Carolina · Active not recruiting

  • WB Contracted Clinical Research Site

    Spartanburg, South Carolina · Active not recruiting

  • WB Contracted Clinical Research Site

    Austin, Texas · Active not recruiting

  • WB Contracted Clinical Research Site

    El Paso, Texas · Active not recruiting

  • WB Contracted Clinical Research Site

    McKinney, Texas · Recruiting

  • WB Contracted Clinical Research Site

    San Antonio, Texas · Active not recruiting

  • WB Contracted Clinical Research Site

    Tyler, Texas · Active not recruiting

  • WB Contracted Clinical Research Site

    Richmond, Virginia · Active not recruiting

  • WB Contracted Clinical Research Site

    Buenos Aires, Buenos Aires F.D., Argentina · Active not recruiting

  • WB Contracted Clinical Research Site

    Buenos Aires, Buenos Aires F.D., Argentina · Active not recruiting

  • WB Contracted Clinical Research Site

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • WB Contracted Clinical Research Site

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • WB Contracted Clinical Research Site

    Buenos Aires, Buenos Aires F.D., Argentina · Active not recruiting

  • WB Contracted Clinical Research Site

    Buenos Aires, Buenos Aires F.D., Argentina · Active not recruiting

  • WB Contracted Clinical Research Site

    Córdoba, Córdoba Province, Argentina · Recruiting

  • WB Contracted Clinical Research Site

    Paraná, Entre Ríos Province, Argentina · Recruiting

  • WB Contracted Clinical Research Site

    Rosario, Santa Fe Province, Argentina · Active not recruiting

  • WB Contracted Clinical Research Site

    Rosario, Santa Fe Province, Argentina · Active not recruiting

  • WB Contracted Clinical Research Site

    Santa Fe, Santa Fe Province, Argentina · Recruiting

  • WB Contracted Clinical Research Site

    San Miguel de Tucumán, Tucumán Province, Argentina · Active not recruiting

  • WB Contracted Clinical Research Site

    San Miguel de Tucumán, Tucumán Province, Argentina · Active not recruiting

  • WB Contracted Clinical Research Site

    San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting

  • WB Contracted Clinical Research Site

    Brookvale, New South Wales, Australia · Active not recruiting

  • WB Contracted Clinical Research Site

    Coffs Harbour, New South Wales, Australia · Active not recruiting

  • WB Contracted Clinical Research Site

    Maroubra, New South Wales, Australia · Active not recruiting

  • WB Contracted Clinical Research Site

    Miranda, New South Wales, Australia · Active not recruiting

  • WB Contracted Clinical Research Site

    Wollongong, New South Wales, Australia · Active not recruiting

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.